ACLARIS THERAPEUTICS INC. - COMMON STOCK

Aclaris Therapeutics to Participate in Two March Healthcare Conferences

04 3 2025 07:00:05 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

27 2 2025 06:59:55 提供 Nasdaq GlobeNewswire

New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3

12 2 2025 06:50:01 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Formation of New Scientific Advisory Board

30 1 2025 16:01:21 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

06 1 2025 16:30:00 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

03 12 2024 16:30:00 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

26 11 2024 16:30:00 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics Announces $80 Million Private Placement

18 11 2024 08:10:41 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

18 11 2024 08:10:04 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

06 11 2024 07:00:00 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis

17 9 2024 07:00:00 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

10 9 2024 07:00:00 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

07 8 2024 07:00:00 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million

16 7 2024 16:01:43 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

06 6 2024 07:00:00 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

07 5 2024 16:01:00 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate Update

30 4 2024 07:00:00 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

27 2 2024 07:00:00 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review

16 1 2024 07:00:00 提供 Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis

10 1 2024 07:00:00 提供 Nasdaq GlobeNewswire